Literature DB >> 7180463

Antibody response and opsonization afer pneumococcal vaccination in splenectomized children and healthy persons.

K S Johansen, F K Pedersen.   

Abstract

A significant rise in antibody against pneumococcal types 3, 6A and 25 after pneumococcal vaccination could be demonstrated in 26 of 30 individuals (87%) using an enzyme-linked immunosorbent assay. Similar geometric mean antibody fold increases were found in splenectomized children, non-splenectomized children and healthy adults for types 6A and 25. Splenectomized children exhibited a somewhat lower, but not statistically significant, geometric mean antibody fold increase against type 3 (p = 0.10), as compared to non-splenectomized children. For the whole group a negative correlation could be demonstrated between prevaccination antibody concentration and antibody fold increase after vaccination. After vaccination an enhanced serum opsonic activity against type 3 was found by granulocyte glucose-l-14C oxidation for the whole group of 30 patients (p less than 0.05) but nine individual patients (30%) failed to exhibit an increase. No differences between the three patient groups were demonstrable. Changes in serum opsonic activity could not be detected by a pneumococcal bactericidal assay.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7180463     DOI: 10.1111/j.1699-0463.1982.tb01448.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Immunol Scand C        ISSN: 0108-0202


  3 in total

1.  Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies.

Authors:  W T Jansen; J Gootjes; M Zelle; D V Madore; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

2.  Development of anti-polysaccharide antibodies in asplenic children.

Authors:  L Hammarström; C I Smith
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

3.  Class and subclass anti-pneumococcal antibody responses in splenectomized patients.

Authors:  S Oldfield; S Jenkins; H Yeoman; D Gray; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.